GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label
pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in
patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone
during the run-in period. The study comprises a 2-week enrollment period, 4 week placebo
single blind run in period followed by a 12-week double blind treatment period and a 3-week
follow-up period